251 related articles for article (PubMed ID: 30356039)
1. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
[TBL] [Abstract][Full Text] [Related]
2. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
3. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
4. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
5. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
6. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ
Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026
[TBL] [Abstract][Full Text] [Related]
7. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
8. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
9. Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress.
Herbert KJ; Puliyadi R; Prevo R; Rodriguez-Berriguete G; Ryan A; Ramadan K; Higgins GS
Cell Death Differ; 2021 Apr; 28(4):1333-1346. PubMed ID: 33168956
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032.
Roh E; Han Y; Reddy K; Zykova TA; Lee MH; Yao K; Bai R; Curiel-Lewandrowski C; Dong Z
Oncogene; 2020 May; 39(21):4170-4182. PubMed ID: 32277233
[TBL] [Abstract][Full Text] [Related]
11. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
12. The role of T-LAK cell-originated protein kinase in targeted cancer therapy.
Zhang L; Wang F; Yi H; Ermakova SP; Malyarenko OS; Mo J; Huang Y; Duan Q; Xiao J; Zhu F
Mol Cell Biochem; 2022 Mar; 477(3):759-769. PubMed ID: 35037144
[TBL] [Abstract][Full Text] [Related]
13. TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
Pirovano G; Ashton TM; Herbert KJ; Bryant RJ; Verrill CL; Cerundolo L; Buffa FM; Prevo R; Harrap I; Ryan AJ; Macaulay V; McKenna WG; Higgins GS
Br J Cancer; 2017 Aug; 117(4):503-512. PubMed ID: 28677687
[TBL] [Abstract][Full Text] [Related]
14. T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Thanindratarn P; Wei R; Dean DC; Singh A; Federman N; Nelson SD; Hornicek FJ; Duan Z
Mol Oncol; 2021 Dec; 15(12):3721-3737. PubMed ID: 34115928
[TBL] [Abstract][Full Text] [Related]
15. [
Pirovano G; Roberts S; Brand C; Donabedian PL; Mason C; de Souza PD; Higgins GS; Reiner T
Mol Imaging Biol; 2019 Aug; 21(4):705-712. PubMed ID: 30357568
[TBL] [Abstract][Full Text] [Related]
16. Paeonol suppresses solar ultraviolet-induced skin inflammation by targeting T-LAK cell-originated protein kinase.
Xue P; Wang Y; Zeng F; Xiu R; Chen J; Guo J; Yuan P; Liu L; Xiao J; Lu H; Wu D; Pan H; Lu M; Zhu F; Shi F; Duan Q
Oncotarget; 2017 Apr; 8(16):27093-27104. PubMed ID: 28404919
[TBL] [Abstract][Full Text] [Related]
17. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase.
Diao X; Yang D; Chen Y; Liu W
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
[TBL] [Abstract][Full Text] [Related]
19. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
20. Cell growth inhibition by 3-deoxysappanchalcone is mediated by directly targeting the TOPK signaling pathway in colon cancer.
Zhao R; Huang H; Choi BY; Liu X; Zhang M; Zhou S; Song M; Yin F; Chen H; Shim JH; Bode AM; Dong Z; Lee MH
Phytomedicine; 2019 Aug; 61():152813. PubMed ID: 31035049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
